Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity.
about
Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activityVon Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpuraThe von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura (TTP)Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods.Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies.Thrombotic thrombocytopenic purpura: yesterday, today, tomorrow.Nine years of cascade filtration for thrombotic thrombocytopenic purpura.Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review.von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura.Thrombotic thrombocytopenic purpura and its diagnosis.The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine.Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura.Treatment of thrombotic thrombocytopenic purpura.Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experienceRituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura--haemolytic uraemic syndromeElevated Von Willebrand factor propeptide for the diagnosis of thrombotic microangiopathy and for predicting a poor outcome.Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience.Hematocrit and C-reactive protein predict treatment response times in ADAMTS13-deficient thrombotic microangiopathy.A case of thrombotic thrombocytopenic purpura induced by acute pancreatitis.Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).Treatment with or without plasma exchange for patients with acquired thrombotic microangiopathy not associated with severe ADAMTS13 deficiency: a propensity score-matched study.Thrombotic thrombocytopenic purpura - analysis of clinical features, laboratory characteristics and therapeutic outcome of 24 patients treated at a Tertiary Care Center in Saudi Arabia.Implementation of a rapid assay of ADAMTS13 activity was associated with improved 30-day survival rate in patients with acquired primary thrombotic thrombocytopenic purpura who received platelet transfusions.Eculizumab refractory thrombotic thrombocytopenic purpura secondary to post-endoscopic retrograde cholangiopancreatography pancreatitis in a patient.Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients.Thrombotic thrombocytopenic purpura
P2860
Q24535720-4B8341E5-E2B8-45D5-BE82-68D2CA17744EQ24651320-9D6078D7-3FE2-480D-AC4B-377EE15906EFQ28305837-BAC61722-7D0B-40F2-B819-854BA7C20EF8Q33349688-7BB951E8-A4A1-42E0-B7AD-55ABF07EA229Q33360771-1CFC1AF3-EFFE-4957-AC8D-6D14A8A9FD64Q33361703-A67E5AA1-041D-49FA-A9FD-74050161CF6FQ33361706-D345ADB7-8F64-4FD2-BB41-D3142C04CB06Q33361713-9A8D5071-45D9-4CF9-AC2E-6C5F59DAAA47Q33363572-52B7C3B5-A2E6-4EA5-BE7A-3B5BC4B6C531Q33366296-7DF596BA-4AE7-4475-A999-4925292367B5Q33366493-39CFF943-1E33-458D-8535-B0C85BDD425EQ33369692-32460920-6CEC-429D-9E10-730EFA88741DQ33370956-DDDBBEC4-D43E-49C8-B7A1-FFB58AA9D691Q33380771-33A7ED0B-9FCA-4AE4-BF40-8F13EC303B49Q33389392-7E75C08F-6DE8-4FDB-9A51-0A7869742C4BQ33391086-4938EF4A-D454-4233-824B-F6ED676DFA5EQ33393270-3F704572-6785-4357-9C52-3943EA4017DEQ33393950-9CCABA5E-B056-4CE4-9DCC-BE7571A5032AQ33394765-6D209924-3138-4998-B75E-7D061208E88EQ33400944-EAE0FD9F-2023-4D67-864F-2EE61AE9F76EQ33410829-4CBF5362-2A50-464A-866B-1BDE5BBEF9B0Q33432547-51BF02A2-3BE4-4F72-9DFB-532C38D25760Q33438377-15654535-26A1-4488-82EE-950EE107D3E7Q40203002-1DBBE272-FF56-4F5B-969A-2C2D11A2B741Q42350839-4BFB001B-8C30-45B3-9753-73B7F13B1FCCQ44763754-28F7FB77-1EAE-45D2-93B4-8CBF70E70920Q57591162-F25BF1D9-5363-47E0-B861-89AEBE456FE6
P2860
Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Predicting response to plasma ...... WF-cleaving protease activity.
@ast
Predicting response to plasma ...... WF-cleaving protease activity.
@en
type
label
Predicting response to plasma ...... WF-cleaving protease activity.
@ast
Predicting response to plasma ...... WF-cleaving protease activity.
@en
prefLabel
Predicting response to plasma ...... WF-cleaving protease activity.
@ast
Predicting response to plasma ...... WF-cleaving protease activity.
@en
P2093
P2860
P1433
P1476
Predicting response to plasma ...... WF-cleaving protease activity.
@en
P2093
Hideo Wada
Hideo Yagi
Hiromichi Ishizashi
Hiroshi Shiku
Masanori Matsumoto
Nobuyuki Minami
Tsutomu Nobori
Yoshihiro Fujimura
Yoshitaka Mori
P2860
P304
P356
10.1046/J.1537-2995.2002.00100.X
P577
2002-05-01T00:00:00Z